HOME >> BIOLOGY >> NEWS
Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure

(Philadelphia, PA) The events that lead to cardiac hypertrophy, the enlargement of heart muscle cells, may be stopped by histone deacetylase (HDAC) inhibitors, a class of therapeutic agents currently under development as cancer drugs, according to researchers at the University of Pennsylvania School of Medicine. Cardiac hypertrophy is one of the leading causes of congestive heart failure, the most common diagnosis given for discharged hospital patients in the United States.

In the September issue of Journal of Clinical Investigation, the Penn researchers suggest novel genetic causes for and new therapeutic agents against cardiac hypertrophy and heart failure. Furthermore, the researchers demonstrate that anti-HDAC drugs can block the development of hypertrophy in animal models.

"In our studies, we determined that valproic acid, an HDAC inhibitor used to treat seizure disorders, is effective in preventing heart muscle cells from enlarging," said Jonathan A. Epstein, MD, Associate Professor in the division of Cardiovascular Medicine within Penn's Department of Medicine. "In recent years, drug companies have also begun developing more advanced HDAC inhibitors to treat cancer. These HDAC inhibitors may be among the first known medications to prevent cardiac hypertrophy."

Cardiac hypertrophy can be a healthy physiological response to events, such as aerobic exercise, where heart cells grow larger like any other well-conditioned muscle. Pathological hypertrophy, however, may result from genetic mutation or, most commonly, from the consequences of an unhealthy cardiovascular system.

"The exertion of pushing blood against high resistance in the setting of high blood pressure or overcompensation for heart muscle lost during a heart attack can cause heart muscle cells to enlarge," said Epstein. "While it might be helpful at first, hypertrophy can increase the stress placed on the heart and begin a downward spiral of events that ultimately leads
'"/>

Contact: Greg Lester
lesterg@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
15-Sep-2003


Page: 1 2

Related biology news :

1. Experimental drug shown to block mutant protein causing blood disease
2. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
3. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
4. Experimental Biology 2004 - Translating the Genome
5. Experimental Biology 2004 meets in Washington, D.C. April 17-21
6. Experimental hantavirus vaccine elicits strong antibody response in primates
7. Experimental Biology 2003 meets in San Diego April 11-15
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental gene switch increases lifespan with no ill effects
10. Experimental therapy stops allergic reactions in mice
11. APS awards 44 minority travel fellowships to the Experimental Biology 2002 meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS ... the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s US ... absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
Breaking Biology Technology:
Cached News: